HERCULES, CA — February 8, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), today announced the launch of the Bio-Plex Pro™ Mouse Chemokine Panel, the newest member of its line of magnetic bead–based multiplex immunoassays. The panel enables detection of more samples than any other available assay, allowing researchers to get more data out of each run.
“The most important feature that researchers look for in a chemokine assay kit is the number of samples that can be detected within the assay range, what we call sample detectability,” said Ivan Huang, Bio-Rad Product Manager, Protein Quantitation. “The Bio-Plex Pro Mouse Chemokine Panel offers the industry’s highest sample detectability, producing clear and actionable results.”
Traditional research tools and assays allow scientists to investigate one protein at a time, but the Bio-Plex Pro Mouse Chemokine Panel offers researchers the ability to map out entire networks of protein biomarkers — up to 33 biologically relevant mouse chemokines and cytokines — in a single run from small amounts of sample. For biopharma and researchers using mouse models to study disease and response to treatment, the panel facilitates high throughput and a highly sensitive study of a variety of biomarkers as well as their roles in diverse biological processes across many areas including oncology, immunology, autoimmunity, and infectious diseases.
The Bio-Plex Pro™ Mouse Chemokine Panel offers the ability to map out entire networks of biomarkers — up to 33 biologically relevant mouse chemokines and cytokines — in a single run from small amounts of precious sample.
Benefits of the Bio-Plex Pro Mouse Chemokine Panel include:
- Increased sensitivity and high signal-to-noise ratio — delivers improved sample detectability using reagents that are optimized to provide a broad dynamic range
- Premixed, ready-to-use reagents — streamlines workflow with premixed reagents and a simplified protocol
- Broad panel coverage — detects a broad number of biologically relevant targets in a single well
The Bio-Plex Pro Mouse Chemokine Panel is a ready-to-use, 1 x 96-well kit containing premixed magnetic capture beads and detection antibodies, standards, and buffers. The panel is compatible with the Bio-Plex® 200, Bio-Plex 3D, and the Bio-Plex® MAGPIX™ platforms.
For more information about Bio-Rad’s Bio-Plex product portfolio, please visit www.bio-rad.com/bioplex.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce products to the molecular diagnostics testing market and our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include product quality and liability issues, our ability to develop and market new or improved products, international legal and regulatory risks, and our ability to compete effectively. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Legal notice:
xMAP, Luminex, and MAGPIX are trademarks of Luminex Corporation. The Bio-Plex suspension array system includes fluorescently labeled microsphere and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.
Press contact:
Bio-Rad Laboratories, Inc.
Ivan Huang
510-741-6949
ivan_huang@bio-rad.com
Chempetitive Group
Ken Li
312-532-4675
kli@chempetitive.com